TABLE 1

Baseline demography

	rs1225372					rs7903146
	All	GG	GT	TT	ANOVA	CC	CT	TT	ANOVA
Patients started on sulfonylureas
n	901	382	415	104		380	409	112
Age at Rx (years)	63.8 ± 9.6	63.8 ± 9.6	63.9 ± 9.8	63.7 ± 8.9	0.99	63.8 ± 9.8	64.1 ± 9.6	62.9 ± 8.7	0.53
Age at diagnosis (years)	61.3 ± 9.6	61.5 ± 9.4	61.3 ± 9.8	60.9 ± 9.7	0.84	61.6 ± 9.6	61.3 ± 9.7	60.2 ± 9.3	0.40
BMI average (kg/m²)	28.3 ± 4.6	28.3 ± 4.5	28.4 ± 4.5	27.6 ± 4.7	0.26	28.4 ± 4.6	28.3 ± 4.6	27.7 ± 4.4	0.37
BMI at diagnosis (kg/m²)*	28.1 ± 4.6	27.9 ± 4.6	28.5 ± 4.8	26.8 ± 3.5	0.020	28.1 ± 4.7	28.4 ± 4.7	27.0 ± 3.5	0.049
BMI at start of treatment†	28.0 ± 4.5	28.0 ± 4.6	28.2 ± 4.6	27.0 ± 3.3	0.09	28.2 ± 4.8	28.1 ± 4.6	27.1 ± 3.3	0.13
Sex (% male)	58	57	59	63	0.55	58	57	63	0.63
Dose (% maximum)	28 ± 15	28 ± 14	29 ± 16	29 ± 15	0.75	28 ± 15	29 ± 15	28 ± 14	0.84
Adherence (%)	80 ± 18	80 ± 18	79 ± 18	83 ± 15	0.092	79 ± 18	80 ± 17	82 ± 15	0.31
Metformin
n	945	434	420	91		422	424	99
Age at Rx (years)	60.0 ± 9.5	60.4 ± 9.7	59.5 ± 9.0	61.2 ± 10.5	0.17	60.5 ± 9.6	59.5 ± 9.2	60.6 ± 9.9	0.24
Age at diagnosis (years)	57.7 ± 9.4	58.2 ± 9.5	56.9 ± 8.9	59.2 ± 10.4	0.041	58.3 ± 9.4	57.0 ± 9.1	58.4 ± 9.9	0.11
BMI average (kg/m²)	32.8 ± 5.6	33.4 ± 5.7	32.4 ± 5.4	31.4 ± 5.5	0.002	33.3 ± 5.7	32.6 ± 5.4	31.2 ± 5.5	0.003
BMI at diagnosis (kg/m²)‡	33.1 ± 6.0	34.0 ± 6.3	32.4 ± 5.6	31.8 ± 5.6	<0.001	34.0 ± 6.3	32.6 ± 5.6	31.5 ± 5.5	0.001
BMI at start of treatment§	32.9 ± 5.8	33.6 ± 5.9	32.5 ± 5.6	31.3 ± 5.7	0.001	33.5 ± 6.0	32.6 ± 5.5	31.2 ± 5.6	0.001
Sex (% male)	52	47	56	48	0.026	49	54	53	0.28
Dose (% maximum)	19 ± 7	19 ± 7	19 ± 6	19 ± 5	0.38	19 ± 7	19 ± 7	19 ± 7	0.50
Adherence (%)	92 ± 12	91 ± 13	92 ± 11	92 ± 11	0.26	91 ± 14	92 ± 11	93 ± 11	0.16

Data are means ± SD unless otherwise indicated. P < 0.05 are bold.
* n = 643;
† n = 800;
‡ n = 761;
§ n = 893. Rx, treatment.